SCHEMBL20048736

SCHEMBL20048736

COS(=O)c1ccc(F)c(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 4/20 0.39
MAPT P10636 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
MEN1 O00255 5/20 0.38
KMT2A Q03164 5/20 0.38
CASP3 P42574 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
TSHR P16473 2/20 0.36
ALDH1A1 P00352 3/20 0.35
LMNA P02545 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
PKM P14618 1/20 0.35
SOS1 Q07889 1/20 0.35
SLC2A1 P11166 1/20 0.34
PTGS2 P35354 1/20 0.34
RPA1 P27694 1/20 0.34
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14305114 0.76 ALDH1A1 (0.38) HTTMAPTRAB9AMEN1KMT2A
SCHEMBL8105141 0.75 SLC2A1 (0.41) HTTMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL15959324 0.74 CYP2A6 (0.42) HTTMAPTNPC1RAB9AMEN1
SCHEMBL21691220 0.73 CYP1A2 (0.39) HTTMAPTNPC1RAB9AMEN1
SCHEMBL3928731 0.73 SLC2A1 (0.40) HTTMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL3928729 0.73 SOS1 (0.37) HTTMAPTMEN1KMT2ATSHR
SCHEMBL17024062 0.71 TSHR (0.38) HTTMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL8151621 0.71 NPC1 (0.36) HTTMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL13209303 0.70 TSHR (0.39) HTTMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL19188309 0.69 ALDH1A1 (0.47) MAPTALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11802110-B2 2-amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase Oxford Drug Design Limited (GB) 2023-10-31 US disclosed
US-20200039929-A1 2-AMINO-N-(ARYLSULFINYL)-ACETAMIDE COMPOUNDS AS INHIBITORS OF BACTERIAL AMINOACYL-TRNA SYNTHETASE INHIBOX LIMITED (GB) 2020-02-06 US disclosed
WO-2018065611-A1 2-AMINO-N-(ARYLSULFINYL)-ACETAMIDE COMPOUNDS AS INHIBITORS OF BACTERIAL AMINOACYL-TRNA SYNTHETASE Oxford Drug Design Limited (GB) 2018-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11802110-B2 2-amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase AARS1, NSUN3, GARS1 HTT 914/4885MAPT 3160/4885SMN1; SMN2 2337/4885
US-20200039929-A1 2-AMINO-N-(ARYLSULFINYL)-ACETAMIDE COMPOUNDS AS INHIBITORS OF BACTERIAL AMINOACYL-TRNA SYNTHETASE AARS1, NSUN3, GARS1 HTT 914/4885MAPT 3160/4885SMN1; SMN2 2337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.